- Home
- SRRK
as 07-26-2024 4:00pm EST
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 619.7M | IPO Year: | 2018 |
| Target Price: | $26.14 | AVG Volume (30 days): | 899.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.93 - $21.17 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Myles Edward H | SRRK | COO & CFO | Jun 17 '24 | Sell | $8.98 | 9,458 | $84,978.24 | 201,518 | SEC Form 4 |
| Parlavecchio Caryn | SRRK | CHRO | Jun 17 '24 | Sell | $8.98 | 4,305 | $38,679.99 | 153,439 | SEC Form 4 |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jun 17 '24 | Sell | $8.99 | 2,315 | $20,800.27 | 144,704 | SEC Form 4 |
| Ho Junlin | SRRK | GENERAL COUNSEL | Jun 17 '24 | Sell | $8.98 | 4,695 | $42,182.70 | 204,076 | SEC Form 4 |
| Myles Edward H | SRRK | COO & CFO | Feb 16 '24 | Sell | $15.74 | 4,744 | $74,685.74 | 210,976 | SEC Form 4 |
| Parlavecchio Caryn | SRRK | CHRO | Feb 16 '24 | Sell | $15.74 | 3,751 | $59,052.74 | 157,744 | SEC Form 4 |
| Ho Junlin | SRRK | GENERAL COUNSEL | Feb 16 '24 | Sell | $15.74 | 3,489 | $54,928.02 | 208,771 | SEC Form 4 |
| Backstrom Jay T. | SRRK | CHIEF EXECUTIVE OFFICER | Feb 16 '24 | Sell | $15.74 | 11,614 | $182,841.52 | 352,671 | SEC Form 4 |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Feb 16 '24 | Sell | $15.74 | 2,512 | $39,546.92 | 147,019 | SEC Form 4 |
| Myles Edward H | SRRK | COO & CFO | Jan 16 '24 | Sell | $15.93 | 6,634 | $105,669.67 | 162,150 | SEC Form 4 |
| Qatanani Mo | SRRK | SVP AND HEAD OF RESEARCH | Jan 16 '24 | Sell | $15.93 | 2,002 | $31,889.26 | 78,816 | SEC Form 4 |
| Ho Junlin | SRRK | GENERAL COUNSEL | Jan 16 '24 | Sell | $15.93 | 4,186 | $66,677.12 | 154,405 | SEC Form 4 |
| Parlavecchio Caryn | SRRK | CHRO | Jan 16 '24 | Sell | $15.93 | 2,849 | $45,381.44 | 114,350 | SEC Form 4 |
| Myles Edward H | SRRK | COO & CFO | Dec 29 '23 | Sell | $18.82 | 12,159 | $228,780.10 | 169,084 | SEC Form 4 |
| Myles Edward H | SRRK | COO & CFO | Dec 29 '23 | Sell | $19.51 | 300 | $5,853.00 | 168,784 | SEC Form 4 |
| Qatanani Mo | SRRK | SVP AND HEAD OF RESEARCH | Dec 14 '23 | Sell | $18.18 | 24,662 | $448,443.94 | 80,818 | SEC Form 4 |
| Myles Edward H | SRRK | COO & CFO | Dec 7 '23 | Sell | $17.53 | 24,914 | $436,819.65 | 168,784 | SEC Form 4 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Scholar Rock to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
Business Wire
14 days ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
18 days ago
Scholar Rock Holding Corporation (SRRK): The Most Shorted Stock Loved by Analysts?
Business Wire
a month ago
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
Business Wire
a month ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
BMO Capital Raises Price Target on Scholar Rock to $31 From $29, Maintains Outperform Rating
CNW Group
2 months ago
Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
PR Newswire
2 months ago
IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
Compare SRRK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.